Patent ID: 8501699
Filing Date: 2013-08-06
Classification: A61P,C07H

Abstract:
1. A compound of formula I for use in treating or preventing a hepatitis C viral infection in a subject suffering from or at risk of a hepatitis C viral infection comprising in vivo production of a therapeutically effective metabolite of the compound of formula I, wherein the metabolite has an intracellular half-life of greater than about 10 hours, and wherein formula I comprises: wherein the A is selected from the group consisting of —O—, —S—, —CH R R is independently halogen, —H, —OH, —SH, —CN, S(C L is selected from the group consisting —O, —S, —NH, —NR, —CY Y is independently selected from the group consisting of —H, halogen, —R, —OR, and —NR R Base is a group of formula II: wherein the Z Z G is independently selected from the group consisting of —H, —F, —Cl, —I, —NH when A is O; R or a pharmaceutically-acceptable salt, ester, solvate, hydrate, or prodrug thereof.